Best Hospitals for Angioplasty & Stenting in UAE

The total cost of angioplasty and coronary stenting in India typically ranges from USD 3,000 to USD 7,000, depending on the complexity of the procedure (single-vessel versus multivessel PCI), the type of stent used (third-generation drug-eluting stents from brands such as Abbott Xience, Medtronic Resolute Onyx, or Biotronik Orsiro), and whether advanced adjunctive technologies such as intravascular imaging (OCT or IVUS) or rotational atherectomy are required. This cost generally includes catheterisation laboratory fees, stent costs, one to three nights in a private hospital room, standard medications including the initial loading dose of dual antiplatelet therapy, nursing care, and cardiologist fees. In the UAE — specifically Dubai and Abu Dhabi — the same procedure at a JCI-accredited hospital such as Cleveland Clinic Abu Dhabi, Mediclinic City Hospital Dubai, or American Hospital Dubai typically costs between USD 8,000 and USD 18,000, reflecting the higher operational costs, luxury hospital infrastructure, and imported premium stent pricing in that market. India is therefore approximately 50–65% less expensive than the UAE for equivalent clinical outcomes. Both destinations offer procedures performed by senior interventional cardiologists trained at leading international institutions, using the same generation of drug-eluting stents and imaging equipment available in Europe or North America. GAF Healthcare provides itemised cost estimates for each patient based on their specific clinical file before any commitment is made.

For most patients undergoing elective single-vessel or two-vessel PCI via the transradial approach without complications, the treating cardiologist will typically provide fitness-to-fly clearance for short-haul flights (under four hours) as early as five to seven days after the procedure. For long-haul intercontinental flights — for example, from India to the UK, or from the UAE to West Africa or North America — a minimum of ten to fourteen days post-procedure in-country stay is recommended by most interventional cardiologists and is consistent with guidance from the British Cardiovascular Society and the European Society of Cardiology. The primary reasons for this recovery period are: ensuring that the access site (radial or femoral artery) is fully healed and there is no haematoma or pseudoaneurysm; confirming haemodynamic stability and that the left ventricular ejection fraction (LVEF) has not deteriorated; allowing adequate time for the loading doses of dual antiplatelet therapy (DAPT) to achieve full platelet inhibition; and reducing the risk of deep vein thrombosis (DVT) associated with prolonged immobility during air travel. Patients who have undergone complex PCI — including multivessel stenting, CTO intervention, rotational atherectomy, or who had periprocedural complications — may require a longer in-country stay of two to three weeks. During the flight itself, patients are advised to ambulate briefly every one to two hours, maintain adequate hydration, wear graduated compression stockings (15–20 mmHg), and carry a copy of their stent card, discharge summary, and current medication list. GAF Healthcare ensures that every patient receives a written fit-to-fly letter from the treating cardiologist and that travel documentation is prepared prior to hospital discharge.

The procedural success rate of contemporary percutaneous coronary intervention (PCI) — defined as achieving less than 20% residual stenosis with TIMI grade 3 (normal) flow and no in-hospital major adverse cardiovascular events (MACE) — exceeds 95 to 98% in high-volume, experienced cardiac centres in both India and the UAE. For elective single-vessel PCI of a straightforward stenosis, success rates in accredited Indian and UAE centres match those published by the American College of Cardiology National Cardiovascular Data Registry (ACC-NCDR) and the European Association of Percutaneous Cardiovascular Interventions (EAPCI). At one year following drug-eluting stent implantation, the rate of major adverse cardiovascular events (MACE — comprising cardiac death, recurrent myocardial infarction, or target vessel revascularisation) is below five percent in most contemporary drug-eluting stent trials, including RESOLUTE-III, BIOSTEMI, and TALENT. For primary PCI in STEMI (heart attack), door-to-balloon times below 90 minutes — the international benchmark — are consistently achieved in partner hospitals with 24/7 primary PCI programmes. Long-term stent patency data shows that third-generation biodegradable-polymer drug-eluting stents have in-stent restenosis rates of three to six percent at two years, a dramatic improvement over bare-metal stents (20–30% restenosis) from the earlier era. For complex cases — chronic total occlusions, multivessel disease, left main interventions — success rates and long-term outcomes depend heavily on the operator's experience and the use of intravascular imaging guidance; GAF Healthcare refers patients exclusively to centres with documented high-volume complex PCI programmes and published outcomes data.